

August 09, 2024

To,

General Manager, Listing Department, Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Mumbai – 400 001 Company code: 533333	The Manager, Listing & Compliance Department The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Company code: FCL
---	---

Subject: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30, 33 and Schedule III (Part A) of SEBI (Listing Obligations and Disclosures) Regulations, 2015, we wish to inform you that the meeting of the Board of Directors held on 09th August, 2024, which commenced at **4.30 P.M.** and concluded at **6.30 P.M.** has *inter-alia* considered and approved;

1. The unaudited Standalone and Consolidated Financial Results of the Company and the Limited Review Reports of the Statutory Auditors thereon for the quarter ended June 30, 2024.
2. The 21st Annual General meeting of the Company will be held on Tuesday, September 10, 2024.
3. Based on the recommendation of the Audit Committee, the re-appointment of M/s. ASL & Co., Chartered Accountants (Firm Registration No.: 101921W) as the Statutory Auditors of the Company for a second term of five consecutive years to hold office from the conclusion of 21st Annual General Meeting till the conclusion of 26th annual general meeting of the Company subject to the approval of the Members at the forthcoming Annual General Meeting.
4. Based on the recommendation of Nomination and Remuneration Committee, the re-appointment of Mrs. Aarti Mitesh Jhunjhunwala (DIN: 07759722), as a Whole-Time Director of the Company for a period of 5 (Five) years with effect from August 14, 2024 upto August 13, 2029 (both days inclusive), subject to the approval of the Members at the forthcoming Annual General Meeting.

5. Based on the recommendation of Nomination and Remuneration Committee, **the appointment of Dr. Amit Prabhakar Pratap (DIN: 08023735)** as an **Additional Director** in the category of Non-Executive, Independent Director of the Company for a term of 5 (Five) consecutive years with effect from August 09, 2024 to hold office upto the ensuing Annual General Meeting subject to the approval of the Members at the forthcoming Annual General Meeting.

As per the requirement of the Circular No. List/Comp/14/2018-19 dated 20th June, 2018 issued by BSE on the subject of enforcement of SEBI Orders regarding appointment of Directors by listed companies we hereby affirm that the Director being appointed is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority.

Further, the details as required under Section V-A of Chapter V of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith as an **Annexure – A**.

Highlights of Consolidated Business

Consolidated Quarter Q1-FY 2024-2025 (Y-o-Y Basis)

1. The Profit after tax (PAT) for the quarter ended has **increased** to **~Rs. 2,920.73 Lakhs** from **~Rs.2,612.92 Lakhs** i.e., a **growth of ~12%**.
2. Operational EBITDA for the quarter has **increased** to **~Rs. 3,528 Lakhs** from **~Rs. 3,153 Lakhs** i.e., a **growth of 11.89 %**.

Highlights of Standalone Business

Standalone Business Quarter Q1-FY 2024-2025 (Y-o-Y Basis)

1. Revenue from Operation for the Quarter has **increased** to **~ Rs. 10,660.94 Lakhs** from **~Rs.8,810.97 Lakhs** i.e., a **growth of 21.01%**.
2. Operational EBITDA for the quarter has **increased** to **~Rs.2,618 Lakhs** from **~Rs. 2,225 Lakhs** i.e., a **growth of 17.66 %**.



Kindly take the same on your records and oblige.

Thanking you,

Yours faithfully,
For FINEOTEX CHEMICAL LIMITED



Sanjay Tibrewala
Executive Director and CFO
DIN: 00218525

Encl: As above

FINEOTEX CHEMICAL LIMITED

(Company Identification Number :L24100MH2004PLC144295)

Regd. Off.:42/43,

Telephone 022-26559174-77, Fax-022-22659178, email : Info@fineotex.com, Website : www.fineotex.com

(₹ In lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024				
PARTICULARS	Quarter ended			Year Ended
	30-06-2024	31-03-2024	30-06-2023	31-03-2024
	Unaudited	Audited	Unaudited	Audited
1 Income				
(a) Revenue from operation	10,660.94	11,846.98	8,810.97	41,892.82
(b) Other Income	424.03	1,351.76	705.48	3,242.37
Total Income	11,084.97	13,198.74	9,516.45	45,135.19
2 Expenses				
(a) Cost of materials consumed	6,639.64	7,390.30	5,249.82	25,318.73
(b) Purchase of stock-in-trade	-	-	-	-
(c) Changes in inventories of finished goods, work-in-process and stock-in-trade	(154.58)	(75.64)	40.42	(338.44)
(d) Employee benefits expenses	486.65	473.81	439.10	1,823.17
(e) Finance costs	10.58	33.41	9.23	81.09
(f) Depreciation and amortization expenses	167.41	119.85	106.02	452.47
(g) Other expenses	1,070.90	1,186.76	856.64	3,743.58
Total expenses	8,220.60	9,128.49	6,701.23	31,080.60
3 Profit before tax (1-2)	2,864.37	4,070.25	2,815.22	14,054.59
4 Tax expenses				
(a) Current Tax	654.94	703.60	529.00	2,850.64
(b) Deferred Tax	24.72	77.48	26.88	141.29
5 Profit after tax (3-4)	2,184.71	3,289.17	2,259.34	11,062.66
6 Other Comprehensive Income (OCI) (net of tax)	(9.46)	(24.11)	0.16	(23.62)
7 Total Comprehensive Income for the period (5+6)	2,175.25	3,265.06	2,259.50	11,039.04
8 Paid-up Equity share capital (Face Value ₹ 2/- each)	2,247.83	2,215.30	2,214.97	2,215.30
9 Other Equity (Including Revaluation Reserve if any)				33,598.52
10 Earnings per Share (of ₹ 2/- each) (for Quarter ended not annualised):				
a. Basic & Diluted (₹/share)	1.94	2.97	2.04	9.99




Notes:

- 1 The above results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 09th August, 2024. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The figures of preceding quarter (i.e., three months ended March 31, 2024) are the balancing figures between the audited figure in respect of the full financial year and the published year to date figures upto the end of third quarter of the preceding financial year, which have been subject to limited review.
- 5 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.
- 6 During the period under review, the company has issued and allotted, Equity Shares and Convertible Warrants, on preferential basis, as detailed herein below:
 - a. Fully Paid 9,70,000 Equity Shares of Rs. 2/- each at Rs. 346/- each (including premium of Rs. 344/- each), aggregating to Rs. 3,356.20 Lakhs
 - b. Partly Paid 26,26,000 Convertible Warrants of Rs. 346/- each (including premium of Rs. 344/- each), aggregating to Rs. 9,088.036 Lakhs; Paid up value Rs. 86.50 each (including premium of Rs. 86/- each) aggregating to Rs. 2,272.009 Lakhs.Each Warrant is convertible into 1 fully paid-up equity share of Rs. 2 each at Rs. 346/- each (including premium of Rs. 344/- each) in 18 months, subject to full payment of the issue price of Rs. 346/- each.
- 7 EPS and Diluted EPS have been calculated after considering the equity shares issued and allotted during the period under review.

The Convertible Warrants issued and allotted during the period are partly paid and are convertible in to Equity only on payment of the full issue price. Therefore the same have not been considered for calculation of EPS and Diluted EPS.
- 8 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 9 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 09th August, 2024.

Place: Mumbai
Date: 09th August, 2024

For and on behalf of the Board of Directors


Surendrakumar Tibrewala
Chairman & Managing Director
DIN 00218394


Sanjay Tibrewala
CFO & Executive Director
DIN 00218525



Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone financial results (the "Statement") of Fineotex Chemical Limited (the "Company") for the quarter ended June 30, 2024, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of the Act, as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement



Finecotex Chemical Limited

Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)

(Shikha Jain)
Partner
Membership No.: 136484
UDIN: 24136484BKFSTM9122



FINEOTEX CHEMICAL LIMITED
(Company Identification Number :L24100MH2004PLC144295)
Regd. Off.:42/43, Manorama Chambers, S V Road, Bandra (W), Mumbai 400050
Telephone 022-26559174-77, Fax-022-22659178, email : Info@fineotex.com, Website : www.fineotex.com

(₹ In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024				
PARTICULARS	Quarter ended			Year Ended
	30-06-2024	31-03-2024	30-06-2023	31-03-2024
	Unaudited	Audited	Unaudited	Audited
1 Income				
(a) Revenue from operation	14,190.06	15,301.72	13,223.32	56,897.04
(b) Other Income (Refer Note No 4 below)	487.50	414.60	364.42	1,653.75
Total Income	14,677.56	15,716.32	13,587.74	58,550.79
2 Expenses				
(a) Cost of materials consumed	9,299.06	9,560.00	8,159.10	34,002.76
(b) Purchase of stock-in-trade	32.91	323.23	122.18	1,412.98
(c) Changes in inventories of finished goods, work-in-process and stock-in-trade	(617.01)	(362.01)	65.02	(534.53)
(d) Employee benefits expenses	560.09	554.27	512.29	2,116.48
(e) Finance costs	24.62	58.49	18.78	133.13
(f) Depreciation and amortization expenses	224.87	185.04	133.40	602.03
(g) Other expenses	1,389.63	1,397.23	1,211.89	5,061.20
Total expenses	10,914.17	11,716.25	10,222.66	42,794.05
3 Profit before tax (1-2)	3,763.39	4,000.07	3,365.08	15,756.74
4 Tax expenses				
(a) Current Tax	814.04	858.31	705.12	3,478.58
(b) Deferred Tax	31.62	94.23	47.04	175.65
5 Profit after tax (3-4)	2,917.73	3,047.53	2,612.92	12,102.51
Attributable to:				
(a) Owners of the Company	2,875.12	3,010.64	2,567.58	11,980.88
(b) Non-Controlling Interest	42.62	36.89	45.35	121.63
6 Other Comprehensive Income (OCI) (net of tax)	(9.46)	(24.11)	0.16	(23.62)
7 Total Comprehensive Income for the period (5+6)	2,908.28	3,023.42	2,613.08	12,078.89
Attributable to:				
(a) Owners of the Company	2,865.66	2,986.53	2,567.74	11,957.26
(b) Non-Controlling Interest	42.62	36.89	45.35	121.63
8 Paid-up Equity share capital (Face Value ₹ 2/- each)	2,247.83	2,215.30	2,214.97	2,215.30
9 Other Equity (Including Revaluation Reserve if any)				42,493.90
10 Earnings per Share (of ₹ 2/- each) (for Quarter ended not annualised):				
a) Basic & Diluted (₹/share)	2.56	2.72	2.32	10.82



Notes:

- 1 The above consolidated results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 09th August, 2024. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The figures of preceding quarter (i.e., three months ended March 31, 2024) are the balancing figures between the audited figure in respect of the full financial year and the published year to date figures upto the end of third quarter of the preceding financial year, which have been subject to limited review.
- 5 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.
- 6 During the period under review, the company has issued and allotted, Equity Shares and Convertible Warrants, on preferential basis, as detailed herein below:
 - a. Fully Paid 9,70,000 Equity Shares of Rs. 2/- each at Rs. 346/- each (including premium of Rs. 344/- each), aggregating to Rs. 3,356.20 Lakhs
 - b. Partly Paid 26,26,000 Convertible Warrants of Rs. 346/- each (including premium of Rs. 344/- each), aggregating to Rs. 9,088.036 Lakhs; Paid up value Rs. 86.50 each (including premium of Rs. 86/- each) aggregating to Rs. 2,272.009 Lakhs.Each Warrant is convertible into 1 fully paid-up equity share of Rs. 2 each at Rs. 346/- each (including premium of Rs. 344/- each) in 18 months, subject to full payment of the issue price of Rs. 346/- each.
- 7 EPS and Diluted EPS have been calculated after considering the equity shares issued and allotted during the period under review.

The Convertible Warrants issued and allotted during the period are partly paid and are convertible in to Equity only on payment of the full issue price. Therefore the same have not been considered for calculation of EPS and Diluted EPS.
- 8 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 9 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 09th August, 2024.

For and on behalf of the Board of Directors


Surendrakumar Tibrewala
Chairman & Managing Director
DIN 00218394


Sanjay Tibrewala
CFO & Executive Director
DIN 00218525

Place: Mumbai
Date: 09th August, 2024



Independent Auditor's Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of Fineotex Chemical Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting "prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



Fineotex Chemical Limited

Independent Auditor's Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4. The Statement includes the results of the following entities:

Name of Entities	Relationship
1. Manya Manufacturing India Private Limited (Formerly Known as Manya Steels Private Limited)	Wholly Owned Subsidiary
2. Fineotex Biotex Healthguard FZE (Formerly Known as Fineotex Specialities FZE)	Wholly Owned Subsidiary
3. Fineotex Malaysia Limited	Wholly Owned Subsidiary
4. FSPL Specialities Private Limited (Formerly Known as Fineotex Specialities Private Limited)	Wholly Owned Subsidiary
5. Finoclean Specialities Private Limited	Wholly Owned Subsidiary
Subsidiaries of Fineotex Malaysia Limited	
6. BT Chemicals SDN.BHD.	Subsidiary
7. BT Biotex SDN.BHD.	Subsidiary
8. Rovatex SDN. BHD.	Subsidiary
9. BT. Biotex Limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the unreviewed and unaudited interim financial information prepared and furnished to us by the management and approved by the Board of Directors of the Parent Company referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of the Act, as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial information of Nine subsidiaries which have not been reviewed and are not audited, whose interim financial information reflects (before eliminating intercompany transactions) total revenue of ₹. 4,034.57 Lakhs and total profit after tax of ₹. 728.85 Lakhs for the quarter ended June 30, 2024, as considered in the consolidated unaudited financial results. These interim financial information are not reviewed and are unaudited and have been prepared and furnished to us by the management of the Parent Company and our opinion on the unaudited consolidated financial results, in so far as it relates to the amounts included in the consolidated unaudited financial results in respect of these subsidiary companies, is based solely on such unreviewed and unaudited interim financial information prepared and furnished to us by the management of the Parent Company and approved by the Board of Directors of the Parent Company.



Fineotex Chemical Limited**Independent Auditor's Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

Our Conclusion on the Statement is not modified in respect of our reliance on the unreviewed and unaudited interim financial information of these subsidiary companies certified by the Management of the Parent Company and approved by the Board of Directors of the Parent Company.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)



(Shikha Jain)
Partner
Membership No.: 136484
UDIN: 24136484BKFSTN4637



Place: Mumbai
Date: 09 August, 2024

Annexure-A

Details required under Schedule III of Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

SN	Particulars	Details		
		Mrs. Aarti Jhunjhunwala	Dr. Amit Prabhakar Pratap	M/s. ASL & Co, Charter Accountant
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Re-appointment	Appointment	Re-appointment
2.	Date and term of Appointment	August 09, 2024 With effect from August 14, 2024 to August 13, 2029	August 09, 2024 With effect from August 09, 2024 to August 08, 2029	August 09, 2024 With effect from the Conclusion of 21 st AGM till the conclusion of the 26 th AGM to be held in the FY 2029-30
3.	Brief Profile (in case of appointment)	Mrs. Aarti Mitesh Jhunjhunwala is a second-generation entrepreneur who has worked in the specialized chemical industry for over 15 years. She has several years of experience working in the family business and has a deep understanding of the products and markets in which it operates.	Mr. Amit Prabhakar Pratap has completed his graduation and post-graduation in Oils, Oleochemicals and Surfactants Technology and obtained Ph. D. (Tech) from Institute of Chemical Technology (formerly UDCT), Mumbai. He has served the Institute as “Prof. J. G. Kane Academic Associate” for two	ASL & Co. is more than 40 years old CA Firm. ASL is providing multifaceted services to its clients in the area of Statutory Audits, Managements audits, Internal audits, System Audits, FEMA approvals, Mergers & Amalgamations & Acquisitions, Project Reports,

		Over the years, she has played a major role in the company's growth, overseeing various functions such as business development, sales, branding, strategy, and new growth initiatives. She has actively pursued global strategic alliances allowing the company to benefit from its leading-edge technologies and cleaner processes.	years, Assistant Professor for nine years and at present working as "Associate Professor" since three years in the Department of Oils, Oleochemicals and Surfactants Technology. He is involved in teaching and research in the field of Oil technology and offered consultancy services to many Indian and Multinational companies for over 20 years.	Financial Management System, International & Local Tax Advisory, Execution and Compliance services since 1980. At present they are serving more than 500 clients. ASL & Co. is subject to Peer Review by Peer Reviewer appointed by ICAI, every 3 years.
4.	Disclosure of relationships between directors (in case of appointment of a director)*	1. Mr. Surendrakumar Tibrewala Chairman & Managing Director – Father 2. Mr. Sanjay Tibrewala Executive & CFO Director - Brother	Nil	Nil
5.	Information as required pursuant to BSE Circular with reference no. LIST/COMP/14/2018-19 and NSE with reference no. NSE/CM L/2018/24, both dated 20th June, 2018	She is not debarred from holding the office of Director by virtue of any order of SEBI or any other authority.	He is not debarred from holding the office of Director by virtue of any order of SEBI or any other authority.	-

**The disclosure of relationship of Mrs. Aarti Mitesh Jhunjhunwala is mentioned above. Except that no other appointee is related to the directors or KMP or promoters of the company.*